Cargando…
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
Autores principales: | Borchmann, Peter, Fosså, Alexander, Długosz-Danecka, Monika, Böll, Boris, Dietlein, Markus, Kobe, Carsten, Goergen, Helen, Engert, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745994/ https://www.ncbi.nlm.nih.gov/pubmed/31723777 http://dx.doi.org/10.1097/HS9.0000000000000052 |
Ejemplares similares
-
Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?
por: Hamadani, Mehdi
Publicado: (2022) -
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
por: Damaschin, Carla, et al.
Publicado: (2021) -
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015) -
Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study
por: Suri, Ajit, et al.
Publicado: (2019) -
Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013)